리보핵산(RNA) 간섭 의학 시장 보고서(2026년)

Ribonucleic acid interference (RNAi) medicine is a therapeutic strategy that utilizes small ribonucleic acid (RNA) molecules to inhibit the expression of specific genes associated with disease progression. It functions by targeting and degrading messenger RNA (mRNA), thereby blocking the synthesis of disease-related proteins within the body.

The primary types of ribonucleic acid interference (RNAi) medicine include small interfering ribonucleic acid, micro ribonucleic acid, short hairpin ribonucleic acid, and other types. Small interfering ribonucleic acid refers to short double-stranded RNA molecules that silence specific genes by targeting messenger RNA for degradation. These medicines utilize delivery methods such as nanoparticles, liposomes, viral vectors, and other advanced delivery approaches. They are applied in areas including oncology, cardiovascular diseases, infectious diseases, genetic disorders, and others, serving end-users such as pharmaceutical companies, biotechnology companies, research institutes, and others.

Tariffs are influencing the ribonucleic acid interference (RNAi) medicine market by increasing the cost of imported oligonucleotide synthesis materials, lipid nanoparticle delivery components, and advanced biologics manufacturing equipment required for large-scale RNAi drug production. This is disrupting global supply chains and delaying clinical and commercial manufacturing timelines, particularly in import-dependent regions such as Asia-Pacific and Latin America. Hardware- and formulation-intensive segments, including siRNA delivery systems and viral vector-based RNAi platforms, are experiencing the greatest impact because of their reliance on cross-border specialty inputs. However, tariffs are encouraging regional manufacturing expansion, localized API production, and strategic supply chain diversification, ultimately strengthening domestic RNA therapeutics ecosystems over the long term.

The ribonucleic acid interference (rnai) medicine market research report is one of a series of new reports from The Business Research Company that provides ribonucleic acid interference (rnai) medicine market statistics, including ribonucleic acid interference (rnai) medicine industry global market size, regional shares, competitors with a ribonucleic acid interference (rnai) medicine market share, detailed ribonucleic acid interference (rnai) medicine market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid interference (rnai) medicine industry. This ribonucleic acid interference (rnai) medicine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ribonucleic acid interference (RNai) medicine market size has grown rapidly in recent years. It will grow from $4.06 billion in 2025 to $4.79 billion in 2026 at a compound annual growth rate (CAGR) of 18.0%. The growth in the historic period can be attributed to discovery of rna interference mechanism, early-stage clinical trial failures in oligonucleotide therapies, improvements in rna synthesis and stabilization technologies, rise of antisense oligonucleotide research, increasing funding for rare disease research initiatives.

The ribonucleic acid interference (RNai) medicine market size is expected to see rapid growth in the next few years. It will grow to $9.17 billion in 2030 at a compound annual growth rate (CAGR) of 17.6%. The growth in the forecast period can be attributed to expansion of regulatory approvals for rna based therapeutics, increasing pipeline of targeted gene silencing drugs, growing adoption of advanced delivery platforms improving cellular uptake, rising orphan drug incentives across global markets, reduction in manufacturing and synthesis costs of oligonucleotide therapies. Major trends in the forecast period include advancement in targeted delivery vectors for rna silencing therapeutics, expansion of long-acting and sustained release rna interference formulations, increasing focus on off-target effect reduction and safety profiling, growing adoption of combination therapies integrating rna interference with monoclonal antibodies and small molecules, expansion into rare genetic disorder treatment indications.

The growing adoption of personalized medicine is expected to drive the growth of the RNAi medicine market going forward. Personalized medicine is a healthcare approach that customizes disease prevention, diagnosis, and treatment according to an individual's genetic profile, lifestyle, and biological characteristics. The adoption of personalized medicine is increasing due to the expanding use of genetic testing and genomic sequencing technologies, which allow healthcare providers to identify individual genetic variations and deliver more accurate, targeted therapies that enhance patient outcomes. RNAi medicine contributes to personalized medicine by enabling targeted gene silencing based on a patient's unique genetic profile and underlying disease mechanism, supporting the development of precision therapies that improve treatment effectiveness while reducing side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and healthcare organization, the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, compared to six approvals in 2022. Therefore, the growing adoption of personalized medicine is driving the growth of the RNAi medicine market.

Major companies operating in the RNAi medicine market are prioritizing technological innovations, such as stimuli-responsive siRNA platforms, to strengthen targeted gene silencing, increase therapeutic precision, and reduce off-target effects in disease treatment. Stimuli-responsive siRNA platforms are advanced RNA interference delivery technologies engineered to activate or release small interfering RNA (siRNA) in response to specific biological or environmental stimuli, including pH variations, enzymes, temperature changes, or disease-specific biomarkers. For instance, in March 2023, Switch Therapeutics Inc., a US-based biotechnology company, introduced the Conditionally Activated siRNA (CASi) platform, a stimuli-responsive siRNA technology. It improves targeted gene silencing, enhances therapeutic precision, and minimizes off-target effects in RNA interference (RNAi)-based therapies for central nervous system disorders. The CASi (Conditionally Activated siRNA) platform incorporates a first-of-its-kind conditional activation mechanism that keeps siRNA therapies inactive until they reach specific disease-associated cellular environments.

In September 2025, Novartis AG, a Switzerland-based pharmaceutical company, entered into a partnership with Shanghai Argo Biopharmaceutical Co., Ltd. to develop and commercialize RNA interference therapeutics targeting cardiometabolic diseases. Through this partnership, the companies aimed to combine Novartis' global expertise in drug development and commercialization with Argo's RNA interference (RNAi) platform technologies to accelerate the development of innovative RNAi-based therapies and expand treatment options for patients with chronic cardiometabolic disorders. Shanghai Argo Biopharmaceutical Co., Ltd. is a China-based biotechnology company focused on developing RNA interference therapeutics and gene-silencing technologies for cardiovascular, metabolic, and other chronic diseases.

Major companies operating in the ribonucleic acid interference (rnai) medicine market report are F. Hoffmann-La Roche Ltd., Novartis AG, Novo Nordisk A/S, Sirius Therapeutics Inc., Alnylam Pharmaceuticals Inc., Switch Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Silence Therapeutics plc, Vir Biotechnology Inc., Arbutus Biopharma Corporation, City Therapeutics Inc., ADARx Pharmaceuticals Inc., Comanche Biopharma Corp., Sirnaomics Ltd., OliX Pharmaceuticals Inc., Nitto BioPharma Inc., Benitec Biopharma Inc., Phio Pharmaceuticals Corp., Ionis Pharmaceuticals, Sarepta Therapeutics, Regeneron Pharmaceuticals, Sanofi, GSK plc

North America was the dominating region in the ribonucleic acid interference (RNAi) medicine market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the ribonucleic acid interference (RNAi) medicine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ribonucleic acid interference (RNAi) medicine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ribonucleic acid interference (RNAi) medicine market consists of sales of antisense oligonucleotides, dicer-substrate RNA, piwi-interacting RNA, and aptamer-RNA conjugates. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ribonucleic Acid Interference (RNAi) Medicine Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses ribonucleic acid interference (rnai) medicine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ribonucleic acid interference (rnai) medicine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ribonucleic acid interference (rnai) medicine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Small Interfering Ribonucleic Acid; Micro Ribonucleic Acid; Short Hairpin Ribonucleic Acid; Other Types
• 2) By Delivery Method: Nanoparticles; Liposomes; Viral Vectors; Other Delivery Methods
• 3) By Application: Oncology; Cardiovascular; Infectious Diseases; Genetic Disorders; Other Applications
• 4) By End User: Pharmaceutical Companies; Biotechnology Companies; Research Institutes; Other End Users
• Subsegments:
• 1) By Small Interfering Ribonucleic Acid: Synthetic Small Interfering Ribonucleic Acid; Lipid Nanoparticle Small Interfering Ribonucleic Acid; Conjugated Small Interfering Ribonucleic Acid; Therapeutic Small Interfering Ribonucleic Acid; Research Grade Small Interfering Ribonucleic Acid; Targeted Delivery Small Interfering Ribonucleic Acid
• 2) By Micro Ribonucleic Acid: Diagnostic Micro Ribonucleic Acid; Therapeutic Micro Ribonucleic Acid; Circulating Micro Ribonucleic Acid; Biomarker Based Micro Ribonucleic Acid; Exosome Derived Micro Ribonucleic Acid; Cancer Associated Micro Ribonucleic Acid
• 3) By Short Hairpin Ribonucleic Acid: Vector Based Short Hairpin Ribonucleic Acid; Viral Delivered Short Hairpin Ribonucleic Acid; Stable Expression Short Hairpin Ribonucleic Acid; Inducible Short Hairpin Ribonucleic Acid; Gene Silencing Short Hairpin Ribonucleic Acid; Research Application Short Hairpin Ribonucleic Acid
• 4) By Other Types: Antisense Oligonucleotide Therapies; Circular Ribonucleic Acid Therapeutics; Aptamer Based Therapeutics; Ribonucleic Acid Nanoparticle Therapeutics; Self Amplifying Ribonucleic Acid Therapeutics; Messenger Ribonucleic Acid Interference Therapeutics
• Companies Mentioned: F. Hoffmann-La Roche Ltd.; Novartis AG; Novo Nordisk A/S; Sirius Therapeutics Inc.; Alnylam Pharmaceuticals Inc.; Switch Therapeutics Inc.; Arrowhead Pharmaceuticals Inc.; Arcturus Therapeutics Holdings Inc.; Silence Therapeutics plc; Vir Biotechnology Inc.; Arbutus Biopharma Corporation; City Therapeutics Inc.; ADARx Pharmaceuticals Inc.; Comanche Biopharma Corp.; Sirnaomics Ltd.; OliX Pharmaceuticals Inc.; Nitto BioPharma Inc.; Benitec Biopharma Inc.; Phio Pharmaceuticals Corp.; Ionis Pharmaceuticals; Sarepta Therapeutics; Regeneron Pharmaceuticals; Sanofi; GSK plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Ribonucleic Acid Interference (RNAi) Medicine Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Ribonucleic Acid Interference (RNAi) Medicine Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Ribonucleic Acid Interference (RNAi) Medicine Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Ribonucleic Acid Interference (RNAi) Medicine Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
  • 4.1.5 Industry 4.0 & Intelligent Manufacturing
• 4.2. Major Trends
  • 4.2.1 Advancement In Targeted Delivery Vectors For Rna Silencing Therapeutics
  • 4.2.2 Expansion Of Long-Acting And Sustained Release Rna Interference Formulations
  • 4.2.3 Increasing Focus On Off Target Effect Reduction And Safety Profiling
  • 4.2.4 Growing Adoption Of Combination Therapies Integrating Rna Interference With Monoclonal Antibodies And Small Molecules
  • 4.2.5 Expansion Into Rare Genetic Disorder Treatment Indications

5. Ribonucleic Acid Interference (RNAi) Medicine Market Analysis Of End Use Industries

• 5.1 Pharmaceutical Companies
• 5.2 Biotechnology Companies
• 5.3 Research Institutes
• 5.4 Hospitals And Specialty Clinics
• 5.5 Contract Research Organizations

6. Ribonucleic Acid Interference (RNAi) Medicine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Ribonucleic Acid Interference (RNAi) Medicine Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Ribonucleic Acid Interference (RNAi) Medicine PESTEL Analysis (Political, Economical, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Ribonucleic Acid Interference (RNAi) Medicine Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Ribonucleic Acid Interference (RNAi) Medicine Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Ribonucleic Acid Interference (RNAi) Medicine Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Ribonucleic Acid Interference (RNAi) Medicine Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Ribonucleic Acid Interference (RNAi) Medicine Market Segmentation

• 9.1. Global Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Small Interfering Ribonucleic Acid, Micro Ribonucleic Acid, Short Hairpin Ribonucleic Acid, Other Types
• 9.2. Global Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Delivery Method, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Nanoparticles, Liposomes, Viral Vectors, Other Delivery Methods
• 9.3. Global Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncology, Cardiovascular, Infectious Diseases, Genetic Disorders, Other Applications
• 9.4. Global Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Pharmaceutical Companies, Biotechnology Companies, Research Institutes, Other End Users
• 9.5. Global Ribonucleic Acid Interference (RNAi) Medicine Market, Sub-Segmentation Of Small Interfering Ribonucleic Acid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Synthetic Small Interfering Ribonucleic Acid, Lipid Nanoparticle Small Interfering Ribonucleic Acid, Conjugated Small Interfering Ribonucleic Acid, Therapeutic Small Interfering Ribonucleic Acid, Research Grade Small Interfering Ribonucleic Acid, Targeted Delivery Small Interfering Ribonucleic Acid
• 9.6. Global Ribonucleic Acid Interference (RNAi) Medicine Market, Sub-Segmentation Of Micro Ribonucleic Acid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Diagnostic Micro Ribonucleic Acid, Therapeutic Micro Ribonucleic Acid, Circulating Micro Ribonucleic Acid, Biomarker Based Micro Ribonucleic Acid, Exosome Derived Micro Ribonucleic Acid, Cancer Associated Micro Ribonucleic Acid
• 9.7. Global Ribonucleic Acid Interference (RNAi) Medicine Market, Sub-Segmentation Of Short Hairpin Ribonucleic Acid, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Vector Based Short Hairpin Ribonucleic Acid, Viral Delivered Short Hairpin Ribonucleic Acid, Stable Expression Short Hairpin Ribonucleic Acid, Inducible Short Hairpin Ribonucleic Acid, Gene Silencing Short Hairpin Ribonucleic Acid, Research Application Short Hairpin Ribonucleic Acid
• 9.8. Global Ribonucleic Acid Interference (RNAi) Medicine Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antisense Oligonucleotide Therapies, Circular Ribonucleic Acid Therapeutics, Aptamer Based Therapeutics, Ribonucleic Acid Nanoparticle Therapeutics, Self Amplifying Ribonucleic Acid Therapeutics, Messenger Ribonucleic Acid Interference Therapeutics

10. Ribonucleic Acid Interference (RNAi) Medicine Market Regional And Country Analysis

• 10.1. Global Ribonucleic Acid Interference (RNAi) Medicine Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Ribonucleic Acid Interference (RNAi) Medicine Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Ribonucleic Acid Interference (RNAi) Medicine Market

• 11.1. Asia-Pacific Ribonucleic Acid Interference (RNAi) Medicine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Ribonucleic Acid Interference (RNAi) Medicine Market

• 12.1. China Ribonucleic Acid Interference (RNAi) Medicine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Ribonucleic Acid Interference (RNAi) Medicine Market

• 13.1. India Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Ribonucleic Acid Interference (RNAi) Medicine Market

• 14.1. Japan Ribonucleic Acid Interference (RNAi) Medicine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Ribonucleic Acid Interference (RNAi) Medicine Market

• 15.1. Australia Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Ribonucleic Acid Interference (RNAi) Medicine Market

• 16.1. Indonesia Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Ribonucleic Acid Interference (RNAi) Medicine Market

• 17.1. South Korea Ribonucleic Acid Interference (RNAi) Medicine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Ribonucleic Acid Interference (RNAi) Medicine Market

• 18.1. Taiwan Ribonucleic Acid Interference (RNAi) Medicine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Ribonucleic Acid Interference (RNAi) Medicine Market

• 19.1. South East Asia Ribonucleic Acid Interference (RNAi) Medicine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Ribonucleic Acid Interference (RNAi) Medicine Market

• 20.1. Western Europe Ribonucleic Acid Interference (RNAi) Medicine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Ribonucleic Acid Interference (RNAi) Medicine Market

• 21.1. UK Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Ribonucleic Acid Interference (RNAi) Medicine Market

• 22.1. Germany Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Ribonucleic Acid Interference (RNAi) Medicine Market

• 23.1. France Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Ribonucleic Acid Interference (RNAi) Medicine Market

• 24.1. Italy Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Ribonucleic Acid Interference (RNAi) Medicine Market

• 25.1. Spain Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Ribonucleic Acid Interference (RNAi) Medicine Market

• 26.1. Eastern Europe Ribonucleic Acid Interference (RNAi) Medicine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Ribonucleic Acid Interference (RNAi) Medicine Market

• 27.1. Russia Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Ribonucleic Acid Interference (RNAi) Medicine Market

• 28.1. North America Ribonucleic Acid Interference (RNAi) Medicine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Ribonucleic Acid Interference (RNAi) Medicine Market

• 29.1. USA Ribonucleic Acid Interference (RNAi) Medicine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Ribonucleic Acid Interference (RNAi) Medicine Market

• 30.1. Canada Ribonucleic Acid Interference (RNAi) Medicine Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Ribonucleic Acid Interference (RNAi) Medicine Market

• 31.1. South America Ribonucleic Acid Interference (RNAi) Medicine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Ribonucleic Acid Interference (RNAi) Medicine Market

• 32.1. Brazil Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Ribonucleic Acid Interference (RNAi) Medicine Market

• 33.1. Middle East Ribonucleic Acid Interference (RNAi) Medicine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Ribonucleic Acid Interference (RNAi) Medicine Market

• 34.1. Africa Ribonucleic Acid Interference (RNAi) Medicine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Ribonucleic Acid Interference (RNAi) Medicine Market, Segmentation By Type, Segmentation By Delivery Method, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Ribonucleic Acid Interference (RNAi) Medicine Market Regulatory and Investment Landscape

36. Ribonucleic Acid Interference (RNAi) Medicine Market Competitive Landscape And Company Profiles

• 36.1. Ribonucleic Acid Interference (RNAi) Medicine Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Ribonucleic Acid Interference (RNAi) Medicine Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Ribonucleic Acid Interference (RNAi) Medicine Market Company Profiles
  • 36.3.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sirius Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Alnylam Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Ribonucleic Acid Interference (RNAi) Medicine Market Other Major And Innovative Companies

• Switch Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Silence Therapeutics plc, Vir Biotechnology Inc., Arbutus Biopharma Corporation, City Therapeutics Inc., ADARx Pharmaceuticals Inc., Comanche Biopharma Corp., Sirnaomics Ltd., OliX Pharmaceuticals Inc., Nitto BioPharma Inc., Benitec Biopharma Inc., Phio Pharmaceuticals Corp., Ionis Pharmaceuticals

38. Global Ribonucleic Acid Interference (RNAi) Medicine Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Ribonucleic Acid Interference (RNAi) Medicine Market

41. Ribonucleic Acid Interference (RNAi) Medicine Market High Potential Countries, Segments and Strategies

• 41.1 Ribonucleic Acid Interference (RNAi) Medicine Market In 2030 - Countries Offering Most New Opportunities
• 41.2 Ribonucleic Acid Interference (RNAi) Medicine Market In 2030 - Segments Offering Most New Opportunities
• 41.3 Ribonucleic Acid Interference (RNAi) Medicine Market In 2030 - Growth Strategies
  • 41.3.1 Market Trend Based Strategies
  • 41.3.2 Competitor Strategies

42. Appendix

• 42.1. Abbreviations
• 42.2. Currencies
• 42.3. Historic And Forecast Inflation Rates
• 42.4. Research Inquiries
• 42.5. The Business Research Company
• 42.6. Copyright And Disclaimer